An in vitro interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug

British Journal of Clinical Pharmacology

Volumn 56, Issue 5, 2003, Pages 537-544

  Iwasa, T ^a   Sano, H ^b   Sugiura, A ^a   Uchiyama, N ^a   Hara, K ^a   Okochi, H ^b   Nakagawa, K ^b   Yasumori, T ^a   Ishizaki, T ^b  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

5 hydroxytryptamine 1B 1D receptor agonist; Antimigrame agent; Human monoamine oxidase (MAO); Interethnic difference; Oxidative deamination; Rizatriptan

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ANTIMIGRAINE AGENT; CLORGYLINE; N (2 AMINOETHYL) 4 CHLOROBENZAMIDE; N (2 AMINOETHYL) 5 (3 FLUOROPHENYL) 4 THIAZOLECARBOXAMIDE; PHENETHYLAMINE; RIZATRIPTAN; SEROTONIN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST;

ADULT; ARTICLE; ASIAN; CAUCASIAN; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG OXIDATION; ENZYME ACTIVITY; ETHNIC DIFFERENCE; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; JAPAN; LIVER MICROSOME; LIVER MITOCHONDRION; MALE; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

ASIAN CONTINENTAL ANCESTRY GROUP; DEAMINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; MONOAMINE OXIDASE; SEROTONIN AGONISTS; TRIAZOLES; TRYPTAMINES;

EID: 0242408421     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01922.x     Document Type: Article

References (40)

1. 1B/D agonists: insights into migraine pathophysiology using rizatriptan. Neurology 2000; 55(Suppl. 2): S8-S14.
2. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60: 1259-1287.
3. Gawel MJ. The new triptans. Can J Clin Pharmacol 1999; 6(Suppl. A): 20A-24A.
4. Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 1998; 38: 748-755.
5. Block GA, Goldstein J, Polis A, Reines SA, Smith ME. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups. Headache 1998; 38: 764-771.
6. Tfelt-Hansen P, Ryan RE. Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials. Neurology 2000; 55(Suppl. 2): S19-S24.
7. Saper JR. The use of rizatriptan in the treatment of acute, multiple migraine attacks. Neurology 2000; 55(Suppl. 2): S15-S18.
8. Silberstein SD. Rizatriptan versus usual care in long-term treatment of migraine. Neurology 2000; 55(Suppl. 2): S25-S28.
9. Vyas KP, Halpin RA, Geer LA, et al. Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. Drug Metab Dispos 2000; 28: 89-95.
10. 1B/1D agonist rizatriptan in healthy volunteers. Br J Clin Pharmacol 1999; 48: 190-196.
11. Slaughter DE, Halpin RA, Davis MR, Maryanchik A, Walsh D, Vyas KP. The in vitro metabolism of rizatriptan by human liver subcellular fractions. 7th North Am ISSX Meeting, 1996:372.
12. Grimsby J, Lan NC, Neve R, Chen K, Shih JC. Tissue distribution of human monoamine oxidase A and B mRNA. J Neurochem 1990; 55: 1166-1169.
13. Benedetti MS, Tipton KF. Monoamine oxidases and related amino oxidases as phase I enzymes in the metabolism of xenobiotics. J Neural Transm 1998; 52: 149-171.
14. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci 1999; 22: 197-217.
15. Lu G, Unge T, Owera-Atepo JB, Shih JC, Ekblom J, Oreland L. Characterization and partial purification of human monoamine oxidase-B expressed in Escherichia coli. Protein Express Purif 1996; 7: 315-322.
16. Youdin MBH, Harshak N, Yoshioka M, Araki H, Mukai Y, Gotto G. Novel substrates and products of amine oxidase catalysed reactions. Biochem Soc Trans 1991; 19: 224-227.
17. Wouters J. Structural aspects of monoamine oxidase and its reversible inhibition. Curr Med Chem 1998; 5: 137-162.
18. Balciuniene J, Syvanen AC, McLeod HL, Pettersson U, Jazin EE. The geographic distribution of monoamine oxidase haplotypes supports a bottleneck during the dispersion of modern humans from Africa. J Mol Evol 2001; 52: 157-163.
19. Syagailo YV, Stober G, Grassle M, et al. Association analysis of the functional monoamine oxidase A gene promoter polymorphism in psychiatric disorders. Am J Med Genet 2001; 105: 168-171.
20. Sasaki T, Hattori M, Sakai T, et al. The monoamine oxidase-A gene and major psychosis in Japanese subjects. Biol Psychiat 1998; 44: 922-924.
21. Balciuniene J, Emilsson L, Oreland L, Pettersson U, Jazin E. Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum Genet 2002; 110: 1-7.
22. Gomez N, Balsa D, Unzeta M. A comparative study of some kinetic and molecular properties of microsomal and mitochondrial monoamine oxidase. Biochem Pharmacol 1988; 37: 3407-3413.
23. Oeda K, Sakaki T, Ohkawa H. Expression of rat liver cytochrome P-450MC: cDNA in Saccharomyces cerevisiae. DNA 1985; 4: 203-210.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
25. Krueger MJ, Singer TP. An examination of the reliability of the radiochemical assay for monoamine oxidases A and B. Anal Biochem 1993; 214: 116-123.
26. Noether GE. Sample size determination for some common nonparametric statistics. J Am Stat Assoc 1987; 82: 645-647.
27. Dixon CM, Park GR, Tarbit MH. Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol 1994; 47: 1253-1257.
28. Rolan P. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia 1997; 17(Suppl. 18): 21-27.
29. Fleishaker JC, Ryan KK, Jansat JM, et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol 2001; 51: 437-441.
30. Weyler W, Hsu YPP, Breakfield XO. Biochemistry and genetics of monoamine oxidase. Pharmacol Ther 1990; 47: 391-417.
31. Westlund KN, Krakower TJ, Kwan SW, Abell CW. Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord. Brain Res 1993; 612: 221-230.
32. Abell CW, Kwan SW. Molecular characterization of monoamine oxidase A and B. Prog Nucl Acid Res Mol Biol 2000; 65: 129-156.
33. Prada MD, Kettler R, Keller HH, et al. From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J. Neural Transm 1990; 29(Suppl.): 279-292.
34. Shimada T, Yamazaki H, Miura H, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogenesis and toxic chemicals. Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
35. Shimada T, Tsumura F, Yamazaki H, Guengerich FP, Inoue K. Characterization of (±)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. Pharmacogenetics 2001; 11: 143-156.
36. Kim RB, Yamazaki H, Chiba K, et al. In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exp Ther 1996; 279: 4-11.
37. Musson DG, Birk KL, Panebianco DL, Gagliano KD, Rogers JD, Goldberg MR. Pharmacokinetics of rizatriptan in healthy elderly subjects. Int J Clin Pharmacol Ther 2001; 39: 447-452.
38. Lee Y, Conroy JA, Stepanavage ME, et al. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. Br J Clin Pharmacol 1999; 47: 373-378.
39. Grimsby J, Zentner M, Shih JC. Identification of a region important for human monoamine oxidase B substrate and inhibitor selectivity. Life Sci 1996; 58: 777-787.
40. Geha RM, Rebrin I, Chen K, Shih JC. Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid. J Biol Chem 2001; 276: 9877-9882.